The company has clearly addressed "the data" piece in their PRESS RELEASE. I emphasize PRESS RELEASE as it was not meant to be an in depth scientific disclosure of data.
Here's their CEO's comment, but wait a minute! He is saying that it looks like Ampion keeps on working past the 12 week treatment!!! Wouldn't that be an important reason to wait and present it in their data? Wouldn't that be more impressive which further differentiates their drug from the rest? But of course it would, but the shorts in this board naturally fail to mention these little details...
Mr. Macaluso further noted “Investigators will continue to monitor the Ampion-treated patients because the data suggest improvement in pain and function beyond the 12 week primary endpoint. Detailed 12 week data analysis from the SPRING study will be released following discussions with the FDA and will be presented at upcoming medical conferences.”
Not only that, when he talks about "broad inclusion criteria for the trial" and a "diverse patient population" that means some of those treated had severe OAK and were train wrecks that could barely walk. Previous OAK trials such as Synvic had a more homogenous patient group that were more ambulatory. This makes AMPE's average 40% improvement in pain even more impressive.
I found it interesting that there was no differences detected by the 2 dosing levels. A single 4ml bolus appears to saturate multiple signaling pathways for an extended period of time. Any correlation with local concentration as a function of time would be useful. Perhaps the 40% pain reduction could be increased if a localized time-release formulation is developed.